Neuromyelitis Optica: New Findings on Pathogenesis

International Review of Neurobiology

Volumn 79, Issue , 2007, Pages 665-688

  Wingerchuk, Dean M ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G;

AUTOIMMUNITY; CENTRAL NERVOUS SYSTEM; HISTORY; HUMAN; METHODOLOGY; MYELOOPTIC NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; REVIEW;

AUTOIMMUNITY; CENTRAL NERVOUS SYSTEM; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; IMMUNOGLOBULIN G; MAGNETIC RESONANCE IMAGING; NEUROMYELITIS OPTICA;

EID: 34248658256     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0074-7742(07)79029-3     Document Type: Review

References (56)

1. Agre P., and Kozono D. Aquaporin water channels: Molecular mechanisms for human diseases. FEBS Lett. 555 (2003) 72-78
2. Amiry-Moghaddam M., and Ottersen O.P. The molecular basis of water transport in the brain. Nat. Rev. Neurosci. 4 (2003) 991-1001
3. Bettelli E., Baeten D., Jager A., Sobel R.A., and Kuchroo V.K. Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in mice. J. Clin. Invest. 116 (2006) 2393-2402
4. Boumpas D.T., Patronas N.J., Dalakas M.C., Hakim C.A., Klippel J.H., and Balow J.E. Acute transverse myelitis in systemic lupus erythematosus: Magnetic resonance imaging and review of the literature. J. Rheumatol. 17 (1990) 89-92
5. Correale J., and Fiol M. Activation of humoral immunity and eosinophils in neuromyelitis optica. Neurology 63 (2004) 2363-2370
6. Cree B.A., Goodin D.S., and Hauser S.L. Neuromyelitis optica. Semin. Neurol. 22 (2002) 105-122
7. Cree B.A., Lamb S., Morgan K., Chen A., Waubant E., and Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64 (2005) 1270-1272
8. de Seze J. Neuromyelitis optica. Arch. Neurol. 60 (2003) 1336-1338
9. Devic E. Myelite aigue compliquee de nevrite optique. Bull. Med. (Paris) 8 (1894) 1033-1034
10. Gold R., and Linington C. Devic's disease: Bridging the gap between laboratory and clinic. Brain 125 (2002) 1425-1427
11. Hummers L.K., Krishnan C., Casciola-Rosen L., Rosen A., Morris S., Mahoney J.A., Kerr D.A., and Wigley F.M. Recurrent transverse myelitis associates with anti-Ro (SSA) autoantibodies. Neurology 62 (2004) 147-149
12. Ishizu T., Osoegawa M., Mei F.J., Kikuchi H., Tanaka M., Takakura Y., Minohara M., Murai H., Mihara F., Taniwaki T., and Kira J. Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain 128 (2005) 988-1002
13. Jarius S., Friedemann P., Aktas O., Franciotta D., Bergamaschi R., Siffrin V., Bauer O., Bluthner M., Hohlfeld R., Vincent A., Seelig H.P., and Zipp F. Antibodies to aquaporin-4 in the diagnosis and differential diagnosis of neuromyelitis optica. Late. Breaking Abstract, 22nd Congress of the European Commitee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Madrid, Spain (2006)
14. Keegan M., Pineda A.A., McClelland R.L., Darby C.H., Rodriguez M., and Weinshenker B.G. Plasma exchange for severe attacks of CNS demyelination: Predictors of response. Neurology 58 (2002) 143-146
15. Keegan M., Konig F., McClelland R., Bruck W., Morales Y., Bitsch A., Panitch H., Lassmann H., Weinshenker B., Rodriguez M., Parisi J., and Lucchinetti C.F. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 366 (2005) 579-582
16. Krishnamoorthy G., Lassmann H., Wekerle H., and Holz A. Spontaneous opticospinal encephalomyelitis in a double-transgenic mouse model of autoimmune T cell/B cell cooperation. J. Clin. Invest. 116 (2006) 2385-2392
17. Lalive P.H., Menge T., Barman I., Cree B.A., and Genain C.P. Identification of new serum autoantibodies in neuromyelitis optica using protein microarrays. Neurology 67 (2006) 176-177
18. Lefkowitz D., and Angelo J.N. Neuromyelitis optica with unusual vascular changes. Arch. Neurol. 41 (1984) 1103-1105
19. Lennon V.A., Wingerchuk D.M., Kryzer T.J., Pittock S.J., Lucchinetti C.F., Fujihara K., Nakashima I., and Weinshenker B.G. A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis. Lancet 364 (2004) 2106-2112
20. Lennon V.A., Kryzer T.J., Pittock S.J., Verkman A.S., and Hinson S.R. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J. Exp. Med. 202 (2005) 473-477
21. Littleton E.T., Jacob A., Boggild M., and Palace J. An audit of the diagnostic usefulness of the NMO-IgG assay for neuromyelitis optica. Mult. Scler. 12 (2006) S156
22. Lucchinetti C., Bruck W., Parisi J., Scheithauer B., Rodriguez M., and Lassmann H. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Ann. Neurol. 47 (2000) 707-717
23. Lucchinetti C.F., Mandler R.N., McGavern D., Bruck W., Gleich G., Ransohoff R.M., Trebst C., Weinshenker B., Wingerchuk D., Parisi J.E., and Lassmann H. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 125 (2002) 1450-1461
24. Manabe Y., Sasaki C., Warita H., Hayashi T., Shiro Y., Sakai K., Kashihara K., and Abe K. Sjogren's syndrome with acute transverse myelopathy as the initial manifestation. J. Neurol. Sci. 176 (2000) 158-161
25. Mandler R.N., Ahmed W., and Dencoff J.E. Devic's neuromyelitis optica: A prospective study of seven patients treated with prednisone and azathioprine. Neurology 51 (1998) 1219-1220
26. Mandler R.N., Dencoff J.D., Midani F., Ford C.C., Ahmed W., and Rosenberg G.A. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in cerebrospinal fluid differ in multiple sclerosis and Devic's neuromyelitis optica. Brain 124 (2001) 493-498
27. Marignier R., De Seze J., Durand-Dubief F., Vukusic S., Zephir H., Vermersch P., Cabre P., Cavillon G., Honnorat J., and Confavreux C. NMO-IgG: A French experience. Mult. Scler. 12 (2006) S4
28. Misu T., Fujihara K., Kakita A., Murakami K., Konno H., Nakamura M., Endo M., Watanabe S., Takahashi T., Nakashima I., Takahashi H., and Itoyama Y. Loss of aquaporin-4 in active perivascular lesions in neuromyelitis optica. 22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Madrid, Spain (2006)
29. Misu T., Fujihara K., Nakamura M., Murakami K., Endo M., Konno H., and Itoyama Y. Loss of aquaporin-4 in active perivascular lesions in neuromyelitis optica: A case report. Tohoku J. Exp. Med. 209 (2006) 269-275
30. Nakashima I., Fujihara K., Fujimori J., Narikawa K., Misu T., and Itoyama Y. Absence of IgG1 response in the cerebrospinal fluid of relapsing neuromyelitis optica. Neurology 62 (2004) 144-146
31. Nakashima I., Fujihara K., Miyazawa I., Misu T., Narikawa K., Nakamura M., Watanabe S., Takahashi T., Nishiyama S., Shiga Y., Sato S., Weinshenker B.G., et al. Clinical and MRI features of Japanese patients with multiple sclerosis positive for NMO-IgG. J. Neurol. Neurosurg. Psychiatr. 77 (2006) 1073-1075
32. Neuhaus O., Farina C., Wekerle H., and Hohlfeld R. Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology 56 (2001) 702-708
33. Nielsen S., Nagelhus E.A., Amiry-Moghaddam M., Bourque C., Agre P., and Ottersen O.P. Specialized membrane domains for water transport in glial cells: High-resolution immunogold cytochemistry of aquaporin-4 in rat brain. J. Neurosci. 17 (1997) 171-180
34. O'Riordan J.I., Gallagher H.L., Thompson A.J., Howard R.S., Kingsley D.P., Thompson E.J., McDonald W.I., and Miller D.H. Clinical, CSF, and MRI findings in Devic's neuromyelitis optica. J. Neurol. Neurosurg. Psychiatr. 60 (1996) 382-387
35. Ortiz de Zarate J.C., Tamaroff L., Sica R.E., and Rodriguez J.A. Neuromyelitis optica versus subacute necrotic myelitis. II. Anatomical study of two cases. J. Neurol. Neurosurg. Psychiatr. 31 (1968) 641-645
36. Pittock S.J., Lennon V.A., Krecke K., Wingerchuk D.M., Lucchinetti C.F., and Weinshenker B.G. Brain abnormalities in neuromyelitis optica. Arch. Neurol. 63 (2006) 390-396
37. Pittock S.J., Lennon V.A., Wingerchuk D.M., Homberger H.A., Lucchinetti C.F., and Weinshenker B.G. The prevalence of non-organ-specific autoantibodies and NMO-IgG in neuromyelitis optica (NMO) and related disorders. Neurology 66 (2006) A307
38. Pittock S.J., Weinshenker B.G., Lucchinetti C.F., Wingerchuk D.M., Corboy J.R., and Lennon V.A. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch. Neurol. 63 (2006) 964-968
39. Poppe A.Y., Lapierre Y., Melancon D., Lowden D., Wardell L., Fullerton L.M., and Bar-Or A. Neuromyelitis optica with hypothalamic involvement. Mult. Scler. 11 (2005) 617-621
40. Ransohoff R.M. A mighty mouse: Building a better model of multiple sclerosis. J. Clin. Invest. 116 (2006) 2313-2316
41. Saida T., Tashiro K., Itoyama Y., Sato T., Ohashi Y., and Zhao Z. Interferon beta-1b is effective in Japanese RRMS patients: A randomized, multicenter study. Neurology 64 (2005) 621-630
42. Storch M.K., Stefferl A., Brehm U., Weissert R., Wallstrom E., Kerschensteiner M., Olsson T., Linington C., and Lassmann H. Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol. 8 (1998) 681-694
43. Weinshenker B.G., O'Brien P.C., Petterson T.M., Noseworthy J.H., Lucchinetti C.F., Dodick D.W., Pineda A.A., Stevens L.N., and Rodriguez M. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann. Neurol. 46 (1999) 878-886
44. Weinshenker B.G., De Seze J., Vermersch P., Pittock S., and Lennon V. The relationship between neuromyelitis optica and systemic autoimmune disease. Neurology 66 (2006) A380-A381
45. Weinshenker B.G., Wingerchuk D.M., Nakashima I., Fujihara K., and Lennon V.A. OSMS is NMO, but not MS: Proven clinically and pathologically. Lancet Neurol. 5 (2006) 110-111
46. Weinshenker B.G., Wingerchuk D.M., Vukusic S., Linbo L., Pittock S.J., Lucchinetti C.F., and Lennon V.A. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann. Neurol. 59 (2006) 566-569
47. Weinstock-Guttman B., Ramanathan M., Lincoff N., Napoli S.Q., Sharma J., Feichter J., and Bakshi R. Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch. Neurol. 63 (2006) 957-963
48. Wingerchuk D.M. Neuromyelitis optica: Current concepts. Front. Biosci. 9 (2004) 834-840
49. Wingerchuk D.M. Evidence for humoral autoimmunity in neuromyelitis optica. Neurol. Res. 28 (2006) 348-353
50. Wingerchuk D.M., and Weinshenker B.G. Neuromyelitis optica: Clinical predictors of a relapsing course and survival. Neurology 60 (2003) 848-853
51. Wingerchuk D.M., and Weinshenker B.G. Neuromyelitis optica. Curr. Treat. Options Neurol. 7 (2005) 173-182
52. Wingerchuk D.M., Hogancamp W.F., O'Brien P.C., and Weinshenker B.G. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 53 (1999) 1107-1114
53. Wingerchuk D.M., Lennon V.A., Pittock S.J., Lucchinetti C.F., and Weinshenker B.G. Revised diagnostic criteria for neuromyelitis optica. Neurology 66 (2006) 1485-1489
54. Yong V.W., Chabot S., Stuve O., and Williams G. Interferon beta in the treatment of multiple sclerosis: Mechanisms of action. Neurology 51 (1998) 682-689
55. Zuliani L., Blanco Y., Tavolato B., Giometto B., Graus F., and Saiz A. Neuromyelitis optica autoantibody (NMO-IgG) in patients with suspected NMO or limited forms of NMO. Mult. Scler. 12 (2006) S155-S156
56. Zuliani L., Lopez de Munain A., Ruiz Martinez J., Olascoaga J., Graus F., and Saiz A. [NMO-IgG antibodies in neuromyelitis optica: A report of 2 cases]. Neurologia 21 (2006) 314-317